Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.45 |
| ▸ | PDE6D | O43924 | 1/20 | 0.45 |
| ▸ | PDE6A | P16499 | 1/20 | 0.45 |
| ▸ | PDE6G | P18545 | 1/20 | 0.45 |
| ▸ | PDE6B | P35913 | 1/20 | 0.45 |
| ▸ | PDE6C | P51160 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958734 | 0.88 | CYP2C19 (0.53) | CYP1A2CYP2C9CYP2C19MRGPRX4MAPT | |
| SCHEMBL2010206 | 0.87 | TSHR (0.46) | CYP1A2CYP2C9CYP2C19MRGPRX4MAPT | |
| SCHEMBL477612 | 0.85 | CYP2C19 (0.59) | CYP1A2CYP2C9CYP2C19MRGPRX4MAPT | |
| SCHEMBL477642 | 0.84 | CYP2C19 (0.58) | CYP1A2CYP2C9CYP2C19MRGPRX4MAPT | |
| SCHEMBL2643391 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19MRGPRX4MAPT | |
| SCHEMBL10566215 | 0.83 | MRGPRX4 (0.49) | MRGPRX4MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL1998119 | 0.82 | CES2 (0.65) | MRGPRX4MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL987643 | 0.82 | MRGPRX4 (0.51) | MRGPRX4MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL25963027 | 0.82 | CA12 (0.64) | MRGPRX4MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL10468226 | 0.82 | ALDH1A1 (0.60) | CYP1A2CYP2C9CYP2C19MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835475-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8501794-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2344463-A2 | 1,2 -THIAZOL YL DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7872033-B2 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2010054024-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2146973-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130953-A2 | 2-IMIN0IS0THIAZ0LE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TBXA2R | CYP1A2 1304/4885CYP2C9 1950/4885CYP2C19 2272/4885 |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CYP1A2 1251/4885CYP2C9 1580/4885CYP2C19 1135/4885 |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CYP1A2 1266/4885CYP2C9 1462/4885CYP2C19 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.